DGAP-News: MOLOGEN AG: Postponement of the Creditors' Meeting for the convertible bond 2017/2025 - Execution in time connection with the Extraordinary General Meeting

PRESS RELEASE N 28 / 2018 of 11/26/2018

MOLOGEN AG: Postponement of the Creditors' Meeting for the convertible bond 2017/2025 - Execution in time connection with the Extraordinary General Meeting

Berlin, 26 November 2018 - The biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900 / WKN A2LQ90) announced to postpone the Creditors' Meeting convened for 29 November on the convertible bond 2017/2025 (ISIN DE000A2DANN4). The Creditors' Meeting will be held at a later date and will probably take place in a timely connection with the Extraordinary General Meeting.

On 21 November 2018, MOLOGEN announced that it had received a request from minority shareholders to convene an Extraordinary General Meeting. This may lead to thematic overlaps between the two meetings, mainly with regard to the adjustment of the terms and conditions for the 2017/2025 convertible bond: among other things, with regard to conversion price, conversion ratio and special right to call the convertible bond. It is the Company's aim to provide comprehensive information, in particular on the overlapping points, also at the Extraordinary General Meeting and thus to ensure the greatest possible transparency. The principle creditor agreed to this procedure in advance.

At the Creditors' Meeting, the bondholders are to vote on the agreement reached with the principle bondholder at the end of October 2018 and the associated adjusted bond terms.

The main bondholder had announced prior to the agreement that he would prematurely terminate the two convertible bonds 2016/2024 (ISIN DE000A2BPDY4) and 2017/2025. Following the agreement reached, the principle bondholder waived its right to exercise the currently existing special termination right that existed until 26 October 2018 due to the capital reduction carried out by the Company in summer 2018. Thus, the immediate maturity of the convertible bonds and the associated immediate repayment obligation of approximately EUR6.4 million were averted and the short-term financing of MOLOGEN AG secured. In return, the Company had offered to amend the terms and conditions of the bonds. The agreement reached with the principle creditor is to be submitted to all bondholders of the 2017/2025 convertible bond for voting at the Creditors' Meeting.

MOLOGEN will announce the new date of the creditors' meeting and the date of the Extraordinary General Meeting in due time.

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.